Red: Urano said as recently as February 17, 2015:
Post# of 30028
Posted On: 02/20/2015 2:04:37 PM
Red: Urano said as recently as February 17, 2015:
"MANF and its receptors are our targets. We are making progress."
He is not speaking about "recombinant MANF injections" here. Clearly you must understand that? Way back in June of 2014 recombinant MANF was his focus, but by September of 2014, he specifically said he preferred "small molecules" targeting "endogenous MANF" in the body. His September 2014 comment matches up with what he said again just last week on February 17th!!
Our patent only has to do with recombinant MANF!! The fact that you, Maui, Zoom, and others don't understand that....is perplexing! It is not helpful to be excited for things that are not true about MANF. There are articles talking about research on MANF that you guys talk about, which are not necessarily even referring to our recombinant MANF patent!!! But you guys don't seem to grasp that.
When Urano expressed his excitement over AMBS' gaining orphan status for MANF/Retinitis Pigmentosa, he was excited because he plans on using our recombinant MANF injections to treat eye damage in wolframs patients. But you interpreted his excitement incorrectly, thinking he was still using recombinant MANF to treat wolframs/diabetes itself. He hasn't talked of that since June 2014!!! Currently, he prefers targeting the endogenous MANF with small molecules. That you and the gang have made the term "small molecules" a point of ridicule has something to do with "group think" influences.
I just don't see how can you continue misunderstanding what Urano has been telling us?
"MANF and its receptors are our targets. We are making progress."
He is not speaking about "recombinant MANF injections" here. Clearly you must understand that? Way back in June of 2014 recombinant MANF was his focus, but by September of 2014, he specifically said he preferred "small molecules" targeting "endogenous MANF" in the body. His September 2014 comment matches up with what he said again just last week on February 17th!!
Our patent only has to do with recombinant MANF!! The fact that you, Maui, Zoom, and others don't understand that....is perplexing! It is not helpful to be excited for things that are not true about MANF. There are articles talking about research on MANF that you guys talk about, which are not necessarily even referring to our recombinant MANF patent!!! But you guys don't seem to grasp that.
When Urano expressed his excitement over AMBS' gaining orphan status for MANF/Retinitis Pigmentosa, he was excited because he plans on using our recombinant MANF injections to treat eye damage in wolframs patients. But you interpreted his excitement incorrectly, thinking he was still using recombinant MANF to treat wolframs/diabetes itself. He hasn't talked of that since June 2014!!! Currently, he prefers targeting the endogenous MANF with small molecules. That you and the gang have made the term "small molecules" a point of ridicule has something to do with "group think" influences.
I just don't see how can you continue misunderstanding what Urano has been telling us?
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼